Study on The Oral Immune Tolerance of CMPA Infants Using Amino Acid Formula

September 1, 2019 updated by: Peking University Third Hospital
The main purpose of this study was to observe the effect of amino acid formula on infants with cow's milk protein allergy; to evaluate the role of food avoidance and Open Food Challenge test in the diagnosis of infants with cow's milk protein allergy; to observe the allergic process in infants with cow's milk protein allergy and to explore the criteria for diagnosis and treatment.

Study Overview

Status

Completed

Detailed Description

This is a multi-center, prospective cohort study. This study plans to recruit 200 subjects. The suitable subject will be enrolled and there are seven visits through the 6-month study. Efficacy parameters are the positive incidence of open food challenge test, growth and development index (Weight, Height, Head circumference;), and the improvement of CMPA symptoms (such as SCORAD, gastrointestinal tract, respiratory, comfort scores).

Study Type

Observational

Enrollment (Actual)

200

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 6 months (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Cow's milk protein allergy infants in 0~6 months

Description

Inclusion Criteria:

  • Age: 0 to 6 months;
  • Subject with cow's milk protein allergy (any clinical signs or symptoms of the skin, gastrointestinal tract, respiratory tract or comfortable tract)
  • Unable to breastfeed;
  • Vital signs are stable;
  • Legal guardian has signed the informed consent.

Exclusion Criteria:

  • Subject with congenital and hereditary metabolic diseases;
  • Digestive tract obstruction;
  • Subject with immunodeficiency diseases;
  • Subject who is allergic to known components of amino acid formula powder;
  • The investigator judges it is not suitable for the subject to participate in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Negative rate of open food challenge test
Time Frame: From baseline to AAF feeding for 6 months
Negative rate =The subjects number with negative results of open food challenge test/total subject number with open food challenge test Unit:% Negative rate range: 0-100% High negative rate indicates the immune tolerance of CMPA infant using AAF
From baseline to AAF feeding for 6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
WAZ(weight for age Z score)
Time Frame: From baseline to AAF feeding for 6 months
Z-scores of anthropometric parameters from baseline on weight=Average(The difference between the measured infant weight and the reference infant weight of the same age and sex/the reference infant weight standard deviation) The increase of WAZ indicated that AAF could promote growth and development.
From baseline to AAF feeding for 6 months
HAZ(height for age Z score)
Time Frame: From baseline until AAF feeding for 6 months
Z-scores of anthropometric parameters from baseline on height=Average(The difference between the measured infant height and the reference infant height of the same age and sex/the reference infant height standard deviation) The increase of HAZ indicated that AAF could promote growth and development.
From baseline until AAF feeding for 6 months
HCAZ(head circumference for age Z score)
Time Frame: From baseline to AAF feeding for 6 months
Z-scores of anthropometric parameters from baseline on head circumference=Average(The difference between the measured infant head circumference and the reference infant head circumference of the same age and sex/the reference infant head circumference standard deviation) The increase of HCAZ indicated that AAF could promote growth and development.
From baseline to AAF feeding for 6 months
SCORAD score
Time Frame: From baseline to AAF feeding for 6 months
An SCORAD evaluation scale was evaluated by the investigator at each visit
From baseline to AAF feeding for 6 months
Gastrointestinal symptom score
Time Frame: From baseline to AAF feeding for 6 months
An Gastrointestinal symptom evaluation scale was evaluated by the investigator at each visit
From baseline to AAF feeding for 6 months
Respiratory symptom score
Time Frame: From baseline to AAF feeding for 6 months
An Respiratory symptom evaluation scale was evaluated by the investigator at each visit
From baseline to AAF feeding for 6 months
Comfort symptom score
Time Frame: From baseline to AAF feeding for 6 months
An Comfort symptom evaluation scale was evaluated by the investigator at each visit
From baseline to AAF feeding for 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Juan Zhang, colleague

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 20, 2015

Primary Completion (Actual)

February 28, 2019

Study Completion (Actual)

April 1, 2019

Study Registration Dates

First Submitted

November 1, 2018

First Submitted That Met QC Criteria

December 6, 2018

First Posted (Actual)

December 7, 2018

Study Record Updates

Last Update Posted (Actual)

September 6, 2019

Last Update Submitted That Met QC Criteria

September 1, 2019

Last Verified

November 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cow's Milk Protein Allergy

Subscribe